CRDL
Cardiol Therapeutics Inc.
$1.03
-3.74%
$118.7M
No data for this timeframe.
Vol
Market Cap$118.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders15 funds
Inst. Value$3.4M
Inst. Activity1 buys / 1 sells
Reddit Sentiment56° Neutral
SEC Reports7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. A6·CIK 0001702123·Prev Close $1.07
Recent Activity
May 26, 2026
SEC
Cardiol Therapeutics filed its management information circular and notice of annual general meeting for June 24, 2026. T
6-K — Impact 2/10
May 14, 2026
SEC
Cardiol Therapeutics announced participation in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Co
6-K — Impact 2/10
May 11, 2026
SEC
Cardiol Therapeutics reported Q1 2026 results: net loss widened to C$10.8M from C$8.3M a year ago, driven by higher R&D
6-K — Impact 5/10
Inst.
MORGAN STANLEY — TRIM
250,421 shares ($338.1K)
Inst.
NATIONAL BANK OF CANADA — ADD
2,323 shares ($3.1K)
Mar 26, 2026
short_volume
Short Volume: CRDL — 61.5% short (0.4M / 0.7M)
Short: 433,942 | Exempt: 0 | TRF Vol: 705,921 | Short Ratio: 61.5% | Off-exchange volume (dark pool
Price Targets
$7.22
+601.3% upside
Strong Buy
Current $1.03
Low $4.90
Median $7.58
High $8.83
4 analysts
$4.90
$8.83
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▼ -7.4% | $-0.12 — $-0.08 | 3% YoY | 3 |
| Next Q | $-0.10 ▼ -10.7% | $-0.14 — $-0.08 | 14% YoY | 3 |
| Current FY | $-0.36 ▲ +4.4% | $-0.49 — $-0.25 | 8% YoY | 4 |
| Next FY | $-0.28 ▼ -18.3% | $-0.43 — $-0.19 | 22% YoY | 3 |
Latest Reports
NEUTRAL
6-K
2/10
Cardiol Therapeutics filed its management information circular and notice of annual general meeting for June 24, 2026. T
May 26, 2026
NEUTRAL
6-K
2/10
Cardiol Therapeutics announced participation in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Co
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $1.1M | NEAR_EXIT |
| TWO SIGMA INVESTMENTS, LP | $721.2K | ADD |
| GOLDMAN SACHS GROUP INC | $448.7K | — |
| MORGAN STANLEY | $338.1K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $310.2K | — |
Reddit Sentiment
56°▼
Neutral
Bearish
Neutral
Bullish
15 institutional holders with $3.4M total value (2,485,756 shares) as of 2026-Q1. Top holders: CITADEL, TWO, GOLDMAN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 819,904 | $1.1M | 33.0% | NEAR_EXIT -76.2% |
| 2 | TWO SIGMA INVESTMENTS, LP | 534,211 | $721.2K | 21.5% | ADD +75.1% |
| 3 | GOLDMAN SACHS GROUP INC | 332,400 | $448.7K | 13.4% | — |
| 4 | MORGAN STANLEY | 250,421 | $338.1K | 10.1% | TRIM -27.3% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 229,806 | $310.2K | 9.3% | — |
| 6 | 1832 Asset Management L.P. | 100,000 | $135.0K | 4.0% | — |
| 7 | CITADEL ADVISORS LLC | 76,600 | $103.4K | 3.1% | NEAR_EXIT -76.2% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 70,396 | $95.0K | 2.8% | — |
| 9 | ROYAL BANK OF CANADA | 21,648 | $29.0K | 0.9% | ADD +58.5% |
| 10 | JONES FINANCIAL COMPANIES LLLP | 19,847 | $24.8K | 0.7% | — |
| 11 | COMMONWEALTH EQUITY SERVICES, LLC | 11,100 | $15.0K | 0.4% | — |
| 12 | Independent Advisor Alliance | 10,000 | $13.5K | 0.4% | — |
| 13 | TD Waterhouse Canada Inc. | 6,900 | $9.5K | 0.3% | — |
| 14 | NATIONAL BANK OF CANADA /FI/ | 2,323 | $3.1K | 0.1% | ADD +36.6% |
| 15 | BARCLAYS PLC | 200 | $270.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 344,463 | 250,421 | -27.3% | $338.1K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 1,701 | 2,323 | +36.6% | $3.1K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 232,345 | 406,935 | +75.1% | $388.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 551,053 | 367,453 | -33.3% | $350.2K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 156,331 | 344,463 | +120.3% | $328.5K | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 544,317 | 151,517 | -72.2% | $143.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 26,455 | 551,053 | +1983.0% | $589.6K | 2025-Q3 |
| MORGAN STANLEY | ADD | 99,881 | 156,331 | +56.5% | $167.3K | 2025-Q3 |
| UBS Group AG | TRIM | 139,244 | 53,490 | -61.6% | $57.2K | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 181,682 | 48,629 | -73.2% | $52.5K | 2025-Q3 |
| Atria Investments, Inc | TRIM | 96,342 | 25,436 | -73.6% | $27.2K | 2025-Q3 |
| NATIONAL BANK OF CANADA /FI/ | NEAR_EXIT | 9,213 | 1,566 | -83.0% | $1.7K | 2025-Q3 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 7,713 | 1,534 | -80.1% | $1.6K | 2025-Q3 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 329,149 | 181,682 | -44.8% | $246.6K | 2025-Q2 |
| UBS Group AG | TRIM | 497,857 | 139,244 | -72.0% | $189.4K | 2025-Q2 |
| Atria Investments, Inc | TRIM | 139,053 | 96,342 | -30.7% | $131.0K | 2025-Q2 |
| ROYAL BANK OF CANADA | ADD | 12,814 | 20,304 | +58.5% | $28.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 234,818 | 497,857 | +112.0% | $482.9K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 204,543 | 59,613 | -70.9% | $57.8K | 2025-Q1 |
| ROYAL BANK OF CANADA | TRIM | 24,801 | 12,814 | -48.3% | $12.0K | 2025-Q1 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 5,885 | 8,563 | +45.5% | $8.1K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,000 | 25 | -98.7% | $24.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 2,650 | 234,818 | +8761.1% | $300.6K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 63,700 | 204,543 | +221.1% | $261.8K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,000 | 11,500 | +187.5% | $14.7K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
6-K
2/10
Cardiol Therapeutics filed its management information circular and notice of annual general meeting
May 26, 2026
NEUTRAL
6-K
2/10
Cardiol Therapeutics announced participation in a fireside chat at the H.C. Wainwright 4th Annual Bi
May 14, 2026
NEUTRAL
6-K
5/10
Cardiol Therapeutics reported Q1 2026 results: net loss widened to C$10.8M from C$8.3M a year ago, d
May 11, 2026
BULLISH
6-K
6/10
Cardiol Therapeutics announced that its Phase II MAvERIC results for CardiolRx in recurrent pericard
May 7, 2026
NEUTRAL
6-K
3/10
Cardiol Therapeutics announced a live interview featuring its CEO discussing the ongoing Phase III M
Apr 14, 2026
NEUTRAL
6-K
2/10
Cardiol Therapeutics Inc. announced the date and record details for its upcoming Annual General Meet
Apr 10, 2026
BULLISH
6-K
8/10
Cardiol Therapeutics announced positive clinical progress across its pipeline, including advancement
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.22 mean target
+601.3% upside
Strong Buy (3.00)
$4.90 Low
$8.83 High
| Metric | Value |
|---|---|
| Current Price | $1.03 |
| Target Low | $4.90 |
| Target Mean | $7.22 |
| Target Median | $7.58 |
| Target High | $8.83 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.12 | $-0.08 | 3.3% | -7.4% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.10 | $-0.14 | $-0.08 | 13.9% | -10.7% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.36 | $-0.49 | $-0.25 | 7.7% | +4.4% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.28 | $-0.43 | $-0.19 | 22.2% | -18.3% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.097 | |
| 7d ago | $-0.090 | -0.007 |
| 30d ago | $-0.090 | -0.007 |
| 60d ago | $-0.100 | +0.003 |
| 90d ago | $-0.100 | +0.003 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
29 mentions
12 bullish
8 bearish
27 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 10, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 23, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 23, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 13, 2026 | 2 | 56° Neutral | 0 | 0 | 2 |
| Apr 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 2 | 50° Neutral | 1 | 1 | 2 |
| Feb 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$CRDL Is the Market Sleeping on This One?
▲ 2
💬 1
⚡ 0.5
Cardiol Therapeutics (CRDL) — DD on a late-stage cardiac biotech heading into a Phase III readout
▲ 1
💬 0
⚡ 0.5
CRDL’s move actually lines up with something
▲ 1
💬 1
⚡ 0.5
CRDL — small pipeline, clear focus
▲ 1
💬 0
⚡ 0.5
CRDL — Phase 3 enrollment quietly moving forward
▲ 1
💬 1
⚡ 0.5
The Pivot to Mass Market Heart Failure ($CRDL)
▲ 1
💬 1
⚡ 0.5
The Pivot to Mass Market Heart Failure ($CRDL)
▲ 1
💬 0
⚡ 0.5
The Pivot to Mass Market Heart Failure ($CRDL)
▲ 1
💬 0
⚡ 0.0
The "Hidden" Data Point in the ARCHER Results ($CRDL)
▲ 8
💬 3
⚡ 0.1
May 21, 2026
Clinical Trial
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Phase Phase 3 — TERMINATED
Mar 26, 2026
short_volume
Short Volume: CRDL — 61.5% short (0.4M / 0.7M)
Short: 433,942 | Exempt: 0 | TRF Vol: 705,921 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)